Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews relevant to all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series should prove to be of interest to all pharmaceutical scientists involved in research in anti-cancer drug design and discovery. The book series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field. The ninth volume of the series features chapters covering the following topics: - New research on the therapeutic intervention of cancer and cancer drug delivery - Dabrafenib usage in melanoma therapy - Targeting autophagy in cancer therapy - Pro-apoptotic and anti-telomerase activity of naturally occurring compounds - CDK inhibitors - Oral nanostructure drug delivery for anti-cancer treatment

Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews relevant to all areas of rational drug design and drug discovery including medicinal chemistry,in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series should prove to be of interest to all pharmaceutical scientists involved in research in anti-cancer drug design and discovery. The book series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field. The tenth volume of the series features chapters covering the following topics: - Challenges in the Management of Hepatoblastoma - The Emerging Role of Monocarboxylate Transporter-1 in Cancer - In-vitro Anti-Proliferative Assays and Techniques Used in Pre-Clinical Anti-Cancer Drug Discovery - Recent Advances in the Development of Mesoporous Anti-Cancer Drug Nanocarriers - Polyphenols and Cancer - Glioblastoma Multiforme - Cutting Edge Targeting Strategies Utilizing Nanotechnology in Breast Cancer Therapy

<p></p> Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews relevant to all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series should prove to be of interest to all pharmaceutical scientists involved in research in anti-cancer drug design and discovery. The book series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field. <p></p> The eleventh volume of the series focuses on reviews on targeted therapies and drug delivery systems. This volume covers the following topics: <p></p> - PI3K/Akt/mTOR Pathway in Acute Lymphoblastic Leukemia Targeted Therapies <p></p> - Polymeric Nanomedicines in Treatment of Breast Cancer: Review of Contemporary Research <p></p> - Treatment of Lung Cancer in the New Era <p></p> - Oral Administration of Cancer Chemotherapeutics Exploiting Self-Nanoemulsifying Drug Delivery System: Recent Progress and Application <p></p> - Targeting Approaches for the Diagnosis and Treatment of Cancer

Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews relevant to all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series should prove to be of interest to all pharmaceutical scientists involved in research in anti-cancer drug design and discovery. The book series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field. This volume of the series focuses on reviews of treatments derived from natural sources (cannabinoid-based medicines and turmeric), immunotherapy, biomarkers for glioblastoma and some new drug targets for anti-cancer treatment. The reviews included in this volume are: - Cannabinoid-Based Anticancer Strategies: - The Beneficial Effects of Turmeric and Its Active Constituent in Cancer Treatment - Immunotherapy Approaches Focusing on Cancer Stem Cells - Immunotherapy for the Treatment of Hepatocellular Carcinoma - Role of Biomarkers in Developing Therapies for Glioblastoma Multiforme - Poly (ADP-ribose) Polymerases as New Drug Targets in Cancer Treatment

&amp;amp;amp;ldquo;Frontiers in Cardiovascular Drug Discovery&amp;amp;amp;rdquo; is an eBook series devoted to publishing the latest and the most important advances in Cardiovascular drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The eBook series should prove to be of interest to all pharmaceutical scientists involved in research in cardiovascular drug design and discovery. Each volume is devoted to the major advances in cardiovascular drug design and discovery. The eBook series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field.

Frontiers in Cardiovascular Drug Discovery is an eBook series devoted to publishing the latest and the most important advances in Cardiovascular drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The eBook series should prove to be of interest to all pharmaceutical scientists involved in research in cardiovascular drug design and discovery. Each volume is devoted to the major advances in cardiovascular drug design and discovery. The eBook series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field.

Frontiers in Cardiovascular Drug Discovery is an eBook series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The eBook series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology. The third volume of the series covers the following topics: - P2Y12 receptor agonists -Heart failure pharmacotherapy -Vasopressin and the cardiovascular system -Cerebral small vessel disease -Complement blocking therapeutic strategies -New antiplatelet and anticoagulating agents for gastrointestinal treatments

Frontiers in Cardiovascular Drug Discovery is an eBook series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The eBook series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology. &lt;/p&gt; &lt;P&gt; The fourth volume of the series covers the following topics: &lt;/p&gt; &lt;p&gt; -Aspirin administration &lt;/p&gt; &lt;p&gt; -Adenosine receptor targeting for cardiovascular therapy &lt;/p&gt; &lt;p&gt; -Drug treatment of patients with coronary stenting &lt;/p&gt; &lt;p&gt; -Immunosuppressive drugs in heart transplantation &lt;/p&gt; &lt;p&gt; -PCSK9 inhibition for lowering LDL-C levels. &lt;/p&gt;

&lt;p&gt;&lt;/p&gt; Frontiers in Cardiovascular Drug Discovery is a book series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The book series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology. &lt;p&gt;&lt;/p&gt; The fifth volume of the series covers the following topics: &lt;p&gt;&lt;/p&gt; -The Lipid Hypothesis: From Resins to Proprotein Convertase Subtilisin/Kexin Type-9 Inhibitors &lt;p&gt;&lt;/p&gt; -The Role of SGLT2i in the Prevention and Treatment of Heart Failure &lt;p&gt;&lt;/p&gt; -Natural Products and Semi-Synthetic Compounds as Antithrombotics: A Review of the Last Ten Years (2009-2019) &lt;p&gt;&lt;/p&gt; -Transient Receptor Potential Channels: Therapeutic Targets for Cardiometabolic Diseases? &lt;p&gt;&lt;/p&gt; -Treatment of Raynaud&rsquo;s Phenomenon &lt;p&gt;&lt;/p&gt; -Traditional Medicine Based Cardiovascular Therapeutics &lt;p&gt;&lt;/p&gt; -Cardiovascular Disease: A Systems Biology Approach

Frontiers in Cardiovascular Drug Discovery is a book series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The book series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology. Volume 6 covers the following topics: - Cardiovascular effects of ranolazine and the scope for translational research: a current review of literature - Rho/Rho kinase signaling pathway and disease: - Hibernation or transformation? Challenges in cardiovascular drug development - New approaches in P2Y12 receptor blocker drugs use - Pathophysiological links between diabetes and cardiovascular diseases: at the biochemical and molecular levels